CN116440081A - 一种槲皮素脂质体的制备方法 - Google Patents
一种槲皮素脂质体的制备方法 Download PDFInfo
- Publication number
- CN116440081A CN116440081A CN202310345729.1A CN202310345729A CN116440081A CN 116440081 A CN116440081 A CN 116440081A CN 202310345729 A CN202310345729 A CN 202310345729A CN 116440081 A CN116440081 A CN 116440081A
- Authority
- CN
- China
- Prior art keywords
- quercetin
- liposome
- manufacturing according
- ceramide
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 title claims abstract description 115
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 title claims abstract description 57
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 title claims abstract description 57
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 title claims abstract description 57
- 235000005875 quercetin Nutrition 0.000 title claims abstract description 57
- 229960001285 quercetin Drugs 0.000 title claims abstract description 57
- 239000002502 liposome Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940106189 ceramide Drugs 0.000 claims abstract description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 11
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims abstract description 10
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims abstract description 10
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims abstract description 10
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims abstract description 10
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 8
- 230000001804 emulsifying effect Effects 0.000 claims abstract description 8
- 238000002390 rotary evaporation Methods 0.000 claims abstract description 8
- 239000002904 solvent Substances 0.000 claims abstract description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 7
- 239000007853 buffer solution Substances 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 6
- 238000010438 heat treatment Methods 0.000 claims abstract description 6
- 229940067606 lecithin Drugs 0.000 claims abstract description 6
- 235000010445 lecithin Nutrition 0.000 claims abstract description 6
- 239000000787 lecithin Substances 0.000 claims abstract description 6
- 229940107161 cholesterol Drugs 0.000 claims abstract description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 3
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims description 2
- BNBSCAZCQDLUDU-DOFZRALJSA-N arachidonoyl amine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(N)=O BNBSCAZCQDLUDU-DOFZRALJSA-N 0.000 claims description 2
- 230000000087 stabilizing effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 7
- 238000005538 encapsulation Methods 0.000 abstract description 7
- 239000002245 particle Substances 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 230000002349 favourable effect Effects 0.000 abstract description 3
- 238000009827 uniform distribution Methods 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000012071 phase Substances 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 9
- 239000000523 sample Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical class CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- -1 i.e. Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- PUGFCQQOYJMKOO-UHFFFAOYSA-N n-(3-hexadecoxy-2-hydroxypropyl)-n-(2-hydroxyethyl)hexadecanamide Chemical compound CCCCCCCCCCCCCCCCOCC(O)CN(CCO)C(=O)CCCCCCCCCCCCCCC PUGFCQQOYJMKOO-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- HXYVTAGFYLMHSO-UHFFFAOYSA-N palmitoyl ethanolamide Chemical compound CCCCCCCCCCCCCCCC(=O)NCCO HXYVTAGFYLMHSO-UHFFFAOYSA-N 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000000886 photobiology Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000037039 plant physiology Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及一种槲皮素脂质体的制备方法,包括如下步骤:(1)将槲皮素、卵磷脂、类神经酰胺和胆固醇加入到溶剂中混合,减压旋蒸,得到油相;(2)配制PBS缓冲液,加入聚乙二醇,混合均匀得到PBS‑PEG溶液,即水相;(3)将水相加入到油相中,水浴加热,然后进行乳化,得到槲皮素脂质体。本发明得到的槲皮素脂质体粒径小且分布均一,包封率高,利于透皮吸收,具有良好的市场应用前景。
Description
技术领域
本发明属于天然植物制剂领域,特别涉及一种槲皮素脂质体的制备方法。
背景技术
槲皮素是天然植物中广泛存在的植物性黄酮醇,具有抗自由基、抗氧化、抗菌、抗病毒、抗炎过敏、防紫外线损伤、抗衰老、防晒、美白、抑制皮肤瘢痕形成等药理作用。据目前研究显示,槲皮素的毒性较低,小鼠灌胃给药LD50约为10-50g/kg,长期应用未见毒性反应以及无明显皮肤刺激作用。鉴于槲皮素广泛的潜在护肤作用,近年来,多国已将槲皮素列入化妆品原料目录。市售的含槲皮素化妆品主要是面霜、乳液、精华、爽肤水等。其中槲皮素与曲酸配伍可增强曲酸的稳定性。
然而,槲皮素的制剂学特征尚不理想,主要问题包括:槲皮素体外稳定性较差(光照不稳定、酸碱不稳定)。因此,通过使用药剂学方法,开发合适槲皮素的载体以提高其在应用中的稳定性,具有较高的潜力和价值。脂质体作为一种新型载体,具有提高其中主药的稳定性的特点。虽然关于制备槲皮素脂质体的研究已有一定的进展(CN202010879360.9、CN201110453651.2、CN201210590103.9),但目前制备的槲皮素脂质体粒径仍然较大,粒径约为200nm,不利于透皮吸收(CN201810376603.X)。
发明内容
本发明所要解决的技术问题是提供一种槲皮素脂质体的制备方法,该方法得到的槲皮素脂质体粒径小且分布均一,包封率高,利于透皮吸收,具有良好的市场应用前景。
本发明提供了一种槲皮素脂质体的制备方法,包括如下步骤:
(1)将槲皮素、卵磷脂、类神经酰胺和胆固醇加入到溶剂中混合,减压旋蒸,得到油相;
(2)配制PBS缓冲液,加入聚乙二醇,混合均匀得到PBS-PEG溶液,即水相;
(3)将水相加入到油相中,水浴加热,然后进行乳化,得到槲皮素脂质体。
所述步骤(1)中的槲皮素、卵磷脂、类神经酰胺的质量比为1-2:35-40:1-2,所述胆固醇与类神经酰胺的摩尔比为1-2:1-2。
所述类神经酰胺为Cetyl-PG羟乙基棕榈酰胺、花生四烯酰胺MEA中的一种或几种。
所述步骤(1)中的溶剂为氯仿、乙醇、乙醚中的一种或几种;所述槲皮素与溶剂的质量体积比为1-2g:200-300mL。
所述步骤(2)中的PBS缓冲液浓度为20-30mmol/L,pH值为7。
所述步骤(2)中的聚乙二醇为PEG200、PEG400中的一种或几种;所述聚乙二醇与PBS缓冲液的体积比为1-2:20-30。
所述步骤(3)中的水浴加热温度为35-40℃,时间为1-2h。
所述步骤(3)中的乳化转速为6000-8000r/min,乳化时间为30min。
所述步骤(3)中乳化后在4℃下稳定2-3h。
类神经酰胺是一类化学物质,用于治疗皮肤问题。它们通过修复皮肤组织,提高肌肤保湿能力,减少皮肤敏感性,从而改善皮肤状况。
有益效果
本发明得到的槲皮素脂质体粒径小且分布均一,包封率高,利于透皮吸收,具有良好的市场应用前景。
附图说明
图1为实施例1得到的槲皮素脂质体的粒径分布;
图2为实施例1和对比组得到的槲皮素脂质体的体外透皮吸收结果。
具体实施方式
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。此外应理解,在阅读了本发明讲授的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
实施例1
(1)油相部分的制备:
1、称取2g槲皮素、36g卵磷脂和2g Cetyl-PG羟乙基棕榈酰胺:胆固醇(1:1摩尔比)置于旋蒸瓶中,加入约300ml氯仿,搅拌超声溶解,至无明显固形物;
2、将旋蒸瓶置于旋蒸蒸发仪上,减压旋蒸5h,水浴温度35℃,将溶液中的氯仿旋蒸至不出溜,此时旋蒸瓶内壁有均匀膜层,即油相。
(2)水相部分的制备:
配制200ml 20mmol/L PBS缓冲液(ph7.0),向上述溶液中加入10ml PEG400,混合均匀得到PBS-PEG溶液,即水相。
(3)乳化:
1、将上述200ml水相加入到油相中,摇晃混合,并于35℃下水浴加热旋转1h,仍有部分固体没有溶解,然后常温超声至无明显固形物,放置4℃过夜保存。
2、使用实验室型乳化机,转速为7000r/min,充分乳化约30min。最后在4℃下稳定2小时,得到槲皮素脂质体。
(4)表征:
使用1μm PES过滤器对所制备的槲皮素脂质体的样品进行过滤,较难过滤,取约2/3的样品进行5000r/min离心10min,样品出现三层(上层为透明的液体层,中间为白色乳化层,下层为黄色的固体层,分析应该是加入的槲皮素);将样品超声混合,然后再次进行乳化约30min后,再次取样测得粒度分布,绝大部分在24nm。
将未离心的部分样品,直接取样进行表征分析,如图1所示,测得粒度分布2789nm、264.9nm、44.7nm分别占比61.7%、27.9%、10.4%。
测试例一槲皮素脂质体包封率测试
采用高效液相色谱,分别检测实施例1得到的槲皮素脂质体中游离槲皮素浓度、脂质体中槲皮素整体浓度,进而计算出槲皮素脂质体的包封率。
实验条件如下
色谱柱:苯基柱,5μm,100A;
流速:1.0ml/min;进样量:10μl;柱温:30℃;
流动相A:0.2%甲酸水、流动相B:甲醇;检测波长:360nm;
梯度洗脱条件:45%A55%B等度洗脱30min。
空白溶剂:甲醇;
对照溶液:称取10mg样品,加入10ml甲醇,振摇溶解,过滤(0.22um滤头)。
样品溶液1(槲皮素上清):取槲皮素脂质体静置2-3天后的上清,并用甲醇稀释10倍后,超声,过滤(0.22um滤头)。
样品溶液2(槲皮素脂质体):将静置后的脂质体,再次超声混匀,并用甲醇稀释20倍后,超声,过滤(0.22um滤头)。
通过上述条件测得槲皮素游离浓度0.13mg/ml;槲皮素脂质体整体浓度为6.49mg/ml。
脂质体包封率计算公式EN%=(1-Cf/Ct)×100%;Cf为游离药物浓度;Ct为脂质体悬液中的药物的总量。
得出实施例1得到的槲皮素脂质体包封率为98%。
测试例二槲皮素脂质体体外透皮实验
实验组为实施例1制备得到的槲皮素脂质体,成分表如下:
No. | 物料名称 | 所占比例(%) |
1 | 槲皮素 | 0.86 |
2 | 氢化溶血卵磷脂 | 15.57 |
3 | Cetyl-PG羟乙基棕榈酰胺(神经酰胺E) | 0.86 |
4 | 胆固醇 | 0.56 |
对比组为根据文献(Liu D,Hu H,Lin Z,et al.Quercetin deformableliposome:preparation and efficacy against ultraviolet B induced skin damagesin vitro and in vivo[J].Journal of Photochemistry and Photobiology B:Biology,2013,127:8-17)制备得到的槲皮素脂质体,成分比表如下:
No. | 物料名称 | 所占比例(%) |
1 | 槲皮素 | 0.86 |
2 | 磷脂酰胆碱 | 16 |
3 | 吐温80 | 4 |
4 | 胆固醇 | 4 |
采用RYJ-12B型药物透皮扩散试验仪,剪取适当大小、完整的皮肤固定在扩散池,使角质层面向供给池,真皮层面向扩散池。接收室中注入生理盐水15ml,分别向供给池中加入上述脂质体各1ml,用铁夹将供给池与接收池的结合部位,保持(37.0±0.1)℃恒温水浴,磁力搅拌保持约500r·min-1,分别于平衡1h、3、5、7、9、12、24h、30h时取出接收室中全部溶液,立即再加等体积、相同温度的新鲜接收液(注意保持皮肤下层与液面紧密接触并排除所有气泡)。样液以0.22μm的微孔滤膜过滤,弃去前1mL的初虑液,精密吸取续滤液20μL,按照高效液相色谱条件测定扩散液中槲皮素的含量[乙引、刘宁.测定植物槲皮素含量的高效液相色谱法[J].植物生理学通讯,2000,36(5):445-446]。
按以下计算公式计算各时间点的单位面积累积透过量(Q,μg·cm2)
Qn为第n个取样点测得的药物质量浓度(μg/ml);Ci为第i(i≤n一1)个取样点测得的药物质量浓度(μg/ml);A:有效透皮面积(1.33cm2);V为接收池中接收液体积(ml)。
结果如图2所示,由图2可以看到实施例1槲皮素脂质体体外透过率要明显高于对比组槲皮素脂质体透过率。
Claims (9)
1.一种槲皮素脂质体的制备方法,包括如下步骤:
(1)将槲皮素、卵磷脂、类神经酰胺和胆固醇加入到溶剂中混合,减压旋蒸,得到油相;
(2)配制PBS缓冲液,加入聚乙二醇,混合均匀得到PBS-PEG溶液,即水相;
(3)将水相加入到油相中,水浴加热,然后进行乳化,得到槲皮素脂质体。
2.根据权利要求1所述的制备方法,其特征在于:所述步骤(1)中的槲皮素、卵磷脂、类神经酰胺的质量比为1-2:35-40:1-2,所述胆固醇与类神经酰胺的摩尔比为1-2:1-2。
3.根据权利要求1或2所述的制备方法,其特征在于:所述类神经酰胺为Cetyl-PG羟乙基棕榈酰胺、花生四烯酰胺MEA中的一种或几种。
4.根据权利要求1所述的制备方法,其特征在于:所述步骤(1)中的溶剂为氯仿、乙醇、乙醚中的一种或几种;所述槲皮素与溶剂的质量体积比为1-2g:200-300mL。
5.根据权利要求1所述的制备方法,其特征在于:所述步骤(2)中的PBS缓冲液浓度为20-30mmol/L,pH值为7。
6.根据权利要求1所述的制备方法,其特征在于:所述步骤(2)中的聚乙二醇为PEG200、PEG400中的一种或几种;所述聚乙二醇与PBS缓冲液的体积比为1-2:20-30。
7.根据权利要求1所述的制备方法,其特征在于:所述步骤(3)中的水浴加热温度为35-40℃,时间为1-2h。
8.根据权利要求1所述的制备方法,其特征在于:所述步骤(3)中的乳化转速为6000-8000r/min,乳化时间为30min。
9.根据权利要求1所述的制备方法,其特征在于:所述步骤(3)中乳化后在4℃下稳定2-3h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310345729.1A CN116440081A (zh) | 2023-04-03 | 2023-04-03 | 一种槲皮素脂质体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310345729.1A CN116440081A (zh) | 2023-04-03 | 2023-04-03 | 一种槲皮素脂质体的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116440081A true CN116440081A (zh) | 2023-07-18 |
Family
ID=87135041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310345729.1A Pending CN116440081A (zh) | 2023-04-03 | 2023-04-03 | 一种槲皮素脂质体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116440081A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117679395A (zh) * | 2023-12-13 | 2024-03-12 | 上海拜思丽实业有限公司 | 一种多肽包覆槲皮素的分子胶囊及其制备方法 |
-
2023
- 2023-04-03 CN CN202310345729.1A patent/CN116440081A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117679395A (zh) * | 2023-12-13 | 2024-03-12 | 上海拜思丽实业有限公司 | 一种多肽包覆槲皮素的分子胶囊及其制备方法 |
CN117679395B (zh) * | 2023-12-13 | 2024-05-17 | 上海拜思丽实业有限公司 | 一种多肽包覆槲皮素的分子胶囊及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112315846B (zh) | 一种裂褶菌多糖脂质体及其制备方法和应用 | |
CN107019690A (zh) | 含类菌胞素氨基酸的创伤治愈用皮肤外用剂组合物及其制造方法 | |
CN116440081A (zh) | 一种槲皮素脂质体的制备方法 | |
CN106361703A (zh) | 非那雄胺纳米脂质体、凝胶及其制备方法 | |
CN107303263B (zh) | 雷公藤多苷纳米乳凝胶及其制备方法 | |
CN104474551B (zh) | 褪黑素磷脂复合物、其透皮给药制剂及其制备方法 | |
JP6151686B2 (ja) | 植物細胞内において安定化した活性物質およびその製造方法 | |
CN113018202A (zh) | 一种铁皮石斛多糖/黄芪多糖复合水凝胶及其制备方法和应用 | |
CN116035973A (zh) | 一种含山茶花提取物的舒缓抗敏组合物及在婴童护肤应用 | |
CN110721149A (zh) | 一种二裂酵母发酵产物滤液组合物的制备方法 | |
AU2004208460B2 (en) | Limposomes containing asiaticoside and the uses thereof | |
CN107638304B (zh) | 一种高皮肤细胞渗透的α-熊果苷组合物及其制备方法和应用 | |
CN113893191A (zh) | 一种基于磷脂包裹的光甘草定纳米乳的美白精华液及其制备方法 | |
CN114533597A (zh) | 一种美白抗老抗病毒的超分子脂质体精华液及其制备方法 | |
CN112641642A (zh) | 基于人参皂苷次生苷的脂质体及其应用 | |
CN110721109A (zh) | 一种蛋白脂质体fnl的制备方法及其在化妆品中的应用 | |
CN109549926A (zh) | 一种pH敏感脂质体的制备方法 | |
CN114533568A (zh) | 一种美白共载离子液体型脂质体及其制备方法 | |
JP3295665B2 (ja) | 美白用皮膚外用剤 | |
RU2207124C1 (ru) | Крем "брамизил" противогрибкового действия | |
CN116725952A (zh) | 一种米诺地尔搽剂的制备方法 | |
Muktadir et al. | Medicament Release from Ointment Bases: III. Ibuprofen: In Vitro Release and In-Vivo Absorption in Rabbits | |
CN115670944B (zh) | 一种具有抗衰功效的微海绵及其制备方法和应用 | |
CN116173190A (zh) | 一种胶原蛋白载体、胶原蛋白纳米粒及其制备方法和应用 | |
CN117815400A (zh) | 银耳纳米囊泡装载光甘草定递送系统及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |